RIPK1 prevents aberrant ZBP1-initiated necroptosis by Vanden Berghe, Tom & Kaiser, William J
Oncotarget1www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/                                  Oncotarget, 2017, Vol. 8, (No. 1), pp: 1-2
RIPK1 prevents aberrant ZBP1-initiated necroptosis
Tom Vanden Berghe and William J. Kaiser
Receptor interacting protein kinase 1 (RIPK1) 
regulates inflammation and cell death, in host defense 
and homeostasis. The adaptor function of RIPK1 allows 
pro-survival and inflammatory signaling, while its 
kinase activity regulates the induction of necroptosis 
and apoptosis. A new level of regulation through its 
RIP homotypic interaction motif (RHIM) was recently 
discovered to suppress necroptosis and inflammation 
driven by the putative nucleic acid sensor protein Z-DNA 
binding protein 1 (ZBP1), also known as DAI.
In the two decades following the discovery of 
RIPK1, RIPK1 has emerged as a master regulator of 
inflammatory signaling and cell death [1]. To date, 
important advances in our understanding of RIPK1 
function continue to be uncovered. RIPK1-deficient 
mice fail to thrive, die within 1-3 days following birth 
and display extensive apoptosis. These observations 
prompted initial research efforts to focus on the role of 
RIPK1 in controlling pro-survival and inflammatory 
gene expression. More recently, RIPK1 kinase activity 
emerged as essential for coordinating death receptor-
induced necrosis (Figure 1A). This type of necrosis was 
dubbed necroptosis upon the discovery of a chemical 
kinase inhibitor of RIPK1, necrostatin-1 (Nec1). However, 
the model of RIPK1 kinase functioning exclusively for 
necroptosis proved too simplistic as kinase activity was 
also found to be crucial for caspase 8-mediated apoptosis 
under conditions where cellular inhibitors of apoptosis 
(cIAPs) are depleted (Figure 1A). Thus, depending on 
the cellular content, RIPK1 kinase can initiate either 
necroptosis or apoptosis. This implies that a protective 
phenotype observed in response to Nec1 or in the context 
of RIPK1 kinase dead knockin mice (Ripk1KD mice) stems 
from the role of RIPK1 in regulating cell death but does 
not differentiate the cell death modality. Conditional 
deletion of RIPK1 in mice revealed additional complexity 
on the regulatory action of RIPK1. While absence of 
RIPK1 unleashes apoptosis in the intestinal epithelial cells 
[2, 3], necroptotic cell death dominates in the skin upon 
RIPK1 depletion [3]. RIPK1 kinase dead knock-in mice 
did not show any spontaneous phenotype indicating the 
sensitization to apoptosis in the gut upon RIPK1 deletion 
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Figure 1: RIPK1 a master regulator of cell death and inflammation. A. Schematic representation of the versatile functions of 
RIPK1. Basically, RIPK1 regulates pro-survival and inflammatory signaling in addition to apoptotic and necroptotic cell death through 
its different regulatory domains viz. adaptor, kinase and RHIM docking function. B. Schematic representation of how the RHIM domain 
of RIPK1 acts as an essential break on constitutive ZBP1 activation. RIPK1 with an inactivating mutation in the RHIM that abolishes 
the capacity of RIPK1 to interact with other cellular RHIM containing proteins induces ZBP1/RIPK3/MLKL- mediated necroptosis 
and inflammation. This defect signaling results in a spontaneous phenotype in the mentioned RIPK1 transgenic mice, which are briefly 
described. IFN, interferon; RIPK, receptor interacting protein kinase; Ripk1mRHIM, mice expressing RIPK1 with an inactivating mutation in 
the RHIM; Ripk1mRHIM/E-KO, mice with skin specific expression of RIPK1 with an inactivating mutation in the RHIM; Ripk1E-KO, mice with 
skin specific deletion of RIPK1; RHIM, RIP homotypic interaction motif; ZBP1, Z-DNA binding protein 1.
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or necroptosis in the skin was not due to the absence of 
kinase activity [4, 5]. In the intestine, the absence the death 
domain in RIPK1 led to excessive apoptosis pointing to 
the essential scaffold function of this domain in RIPK1 
for induction of pro-survival and inflammatory signaling 
(Figure 1A). However, the role of RIPK1 in preventing 
necroptosis in the skin remained unresolved until now. 
In the current issue of Nature, both the Pasparakis 
and Dixit Labs independently reveal that the absence of 
RIPK1 in the skin promotes a necrotic phenotype driven 
by ZBP1, a RHIM-containing protein that has previously 
been shown to mediate virus-induced necroptosis through 
activation of RIPK3/MLKL [6, 7]. As a proof of concept, 
both groups generated mice expressing RIPK1 with an 
inactivating mutation (referred to as Ripk1mRHIM mice) in 
the RHIM that abolishes the capacity of RIPK1 to interact 
with other cellular RHIM containing proteins. Strikingly, 
Ripk1mRHIM mice died around birth with enhanced cell 
death in the skin that correlated with robust levels of 
RIPK3 autophosphorylation. Blocking necroptosis with 
catalytically inactive RIPK3 D161N, RHIM mutant 
RIPK3, RIPK3 deficiency, or MLKL deficiency prevented 
lethality in Ripk1mRHIM mice. Importantly, the loss of ZBP1 
prevented perinatal lethality in Ripk1mRHIM mice, unveiling 
an unexpected role for RIPK1 in preventing ZBP1 
dysregulation. In line with these findings, ZBP1 deficiency 
also prevented the development of skin lesions in mice 
with skin-specific depletion of RIPK1 (Ripk1E-KO mice) or 
skin-specific expression of RIPK1mRHIM (Ripk1mRHIM/E-KO 
mice) [7]. Mechanistically, ZBP1 interacted strongly with 
phosphorylated RIPK3 in cells expressing RIPK1mRHIM, 
suggesting that the RIPK1 RHIM may prevent ZBP1 
from binding and activating RIPK3 (Figure 2B). However, 
both studies were unable to detect constitutive interaction 
between RIPK1 and ZBP1. Similar to RIPK3 knock out 
mice [1], elimination of ZBP1, but not the other cellular 
RHIM-containing protein TRIF, also rescued the perinatal 
lethality of RIPK1/Caspase 8-deficient mice [6]. In 
summary, at least three independent transgenic approaches 
underscore the suppressive role of RIPK1 on ZBP1-
induced necroptosis and inflammation.
What could be the reason of the death at birth of 
Ripk1mRHIM mice? Given that Ripk1mRHIM/E-KO mice are 
viable, the lethality of Ripk1mRHIM mice is unlikely driven 
by increased cell death and/or inflammation in the skin. 
It is tempting to speculate that in Ripk1mRHIM mice, 
exposure to microbes after birth initiates lethal ZBP1/
RIPK3/MLKL-driven inflammation similar to systemic 
inflammatory response syndrome (SIRS). It is remarkable 
that, except for the skin, no significant increase in cell 
death was observed in Ripk1mRHIM mice. Undetectable 
levels of necroptotic cell death in cells other than the 
epidermis could be sufficient to initiate inflammation and 
consequent SIRS-induced shock. Additional research will 
need to distinguish whether ZBP1 functions as merely an 
interferon inducible RHIM-adapter protein or as a bona 
fide nucleic acid sensor surveilling RNA or DNA derived 
from microbes or even endogenous nucleic acids, perhaps 
from damaged tissue. Furthermore, additional studies 
will be necessary to resolve whether RIPK1 functions 
as an essential brake on constitutive ZBP1 activation 
or as a potential sink for RIPK3 limiting activation by 
RIPK1. Nonetheless, these two studies have illuminated 
an unexpected role for ZBP1 in inflammation and the 
importance of RHIM interactions in both driving as well 
as limiting cell death.
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